Cytochrome P450 Inactivation by Pharmaceuticals and Phytochemicals: Therapeutic Relevance

REFERENCES

• Abernethy D. R., Greenblatt D. J., Shader R. I. Imipramine-cimetidine interaction: impairment of clearance and enhanced absolute bioavailability. J. Pharmacol. Exp. Ther. 1984; 229: 702–705
   PubMed Web of Science ®Google Scholar
• Abreo K., LaBarre J. Suprofen, acute renal failure, and hematuria. Ann. Intern. Med. 1986; 105: 799
   PubMed Web of Science ®Google Scholar
• Alderman J., Preskorn S. H., Greenblatt D. J., Harrison W., Penenberg D., Allison J., Chung M. Desipramine pharmacokinetics when coadministered with paroxetine or sertraline in extensive metabolizers. J. Clin. Psychopharmacol. 1997; 17: 284–291
   PubMed Web of Science ®Google Scholar
• Almeida J. C., Grimsley E. W. Coma from the health food store: interaction between kava and alprazolam. Ann. Intern. Med. 1996; 125: 940–941
   PubMed Web of Science ®Google Scholar
• Alvarez-Diez T. M., Zheng J. Mechanism-based inactivation of cytochrome P450 3A4 by 4-ipomeanol. Chem. Res. Toxicol. 2004; 17: 150–157
   PubMed Web of Science ®Google Scholar
• Amsterdam J. D., Brunswick D. J., Potter L., Kaplan M. J. Cimetidine-induced alterations in desipramine plasma concentrations. Psychopharmacol. (Berl). 1984; 83: 373–375
   PubMed Web of Science ®Google Scholar
• Anderson T. F., Voorhees J. J. Psoralen photochemotherapy of cutaneous disorders. Annu. Rev. Pharmacol. Toxicol. 1980; 20: 235–257
   PubMed Web of Science ®Google Scholar
• Anderson P., Bondesson U., de Faire U. Pharmacokinetics of verapamil in patients with hypertension. Eur J Clin Pharmacol. 1986; 31: 155–163
   PubMed Web of Science ®Google Scholar
• Askmark H., Wiholm B. E. Epidemiology of adverse reactions to carbamazepine as seen in a spontaneous reporting system. Acta. Neurol. Scand. 1990; 81: 131–140
   PubMed Web of Science ®Google Scholar
• Bajpai M., Roskos L. K., Shen D. D., Levy R. H. Roles of cytochrome P4502C9 and cytochrome P4502C19 in the stereoselective metabolism of phenytoin to its major metabolite. Drug Metab. Dispos. 1996; 24: 1401–1403
   PubMed Web of Science ®Google Scholar
• Beier R.C. Natural pesticides and bioactive components in foods. Rev. Environ. Contam. Toxicol. 1990; 113: 47–137
   PubMed Web of Science ®Google Scholar
• Benowitz N. L., Nguyen T. L., Jones R. T., Herning R. I., Bachman J. Metabolic and psychophysiologic studies of cannabidiol-hexobarbital interaction. Clin. Pharmacol. Ther. 1980; 28: 115–120
   PubMed Web of Science ®Google Scholar
• Bensoussan C., Delaforge M., Mansuy D. Particular ability of cytochromes P450 3A to form inhibitory P450-iron-metabolite complexes upon metabolic oxidation of aminodrugs. Biochem. Pharmacol. 1995; 49: 591–602
   PubMed Web of Science ®Google Scholar
• Bertelsen K. M., Venkatakrishnan K., Von Moltke L. L., Obach R. S., Greenblatt D. J. Apparent mechanism-based inhibition of human CYP2D6 in vitro by paroxetine: comparison with fluoxetine and quinidine. Drug Metab. Dispos. 2003; 31: 289–293
   PubMed Web of Science ®Google Scholar
• Bestervelt L. L., Vaz A. D., Coon M. J. Inactivation of ethanol-inducible cytochrome P450 and other microsomal P450 isozymes by trans-4-hydroxy-2-nonenal, a major product of membrane lipid peroxidation. Proc. Natl. Acad. Sci. USA 1995; 92: 3764–3768
   PubMed Web of Science ®Google Scholar
• Blobaum A. L. Mechanism-based inactivation and reversibility: is there a new trend in the inactivation of cytochrome p450 enzymes?. Drug Metab Dispos. 2006; 34: 1–7
   PubMed Web of Science ®Google Scholar
• Blumenthal M. German Federal Institute for Drugs and Medical. The Complete German Commission E Monographs: Therapeutic Guide to Herbal Medicines, W. R. Busse, C. Riggins, R. Rister. American Botanical Council, Boston 1998, (trans Klein, S.).
   Google Scholar
• Bochner F., Hooper W. D., Sutherland J. M., Eadie M. J., Tyrer J. H. The renal handling of diphenylhydantoin and 5-(p-hydroxyphenyl)-5-phenylhydantoin. Clin. Pharmacol. Ther. 1973; 14: 791–796
   PubMed Web of Science ®Google Scholar
• Bourdi M., Larrey D., Nataf J., Bernuau J., Pessayre D., Iwasaki M., Guengerich F. P., Beaune P. H. Anti-liver endoplasmic reticulum autoantibodies are directed against human cytochrome P-450IA2. A specific marker of dihydralazine-induced hepatitis. J. Clin. Invest. 1990; 85: 1967–1973
   PubMed Web of Science ®Google Scholar
• Bornheim L. M., Everhart E. T., Li J., Correia M. A. Characterization of cannabidiol-mediated cytochrome P450 inactivation. Biochem. Pharmacol. 1993; 45: 1323–1331
   PubMed Web of Science ®Google Scholar
• Brady J. F., Ishizaki H., Fukuto J. M., Lin M. C., Fadel A., Gapac J. M., Yang C. S. Inhibition of cytochrome P-450 2E1 by diallyl sulfide and its metabolites. Chem. Res. Toxicol. 1991; 4: 642–647
   PubMed Web of Science ®Google Scholar
• Bumpus N. N., Kent U. M., Hollenberg P. F. Metabolism of efavirenz and 8‐hydroxyefavirenz by P450 2B6 leads to inactivation by two distinct mechanisms. J. Pharmacol. Exp. Ther. 2006; 318: 345–351
   PubMed Web of Science ®Google Scholar
• Cadepond F., Ulmann A., Baulieu E. E. RU486 (mifepristone): mechanisms of action and clinical uses. Annu. Rev. Med. 1997; 48: 129–156
   PubMed Web of Science ®Google Scholar
• Cai Y., Bennett D., Nair R. V., Ceska O., Ashwood-Smith M. J., DiGiovanni J. Inhibition and inactivation of murine hepatic ethoxy- and pentoxyresorufin O-dealkylase by naturally occurring coumarins. Chem. Res. Toxicol. 1993; 6: 872–879
   PubMed Web of Science ®Google Scholar
• Cai Y., Baer-Dubowska W., Ashwood-Smith M. J., Ceska O., Tachibana S., DiGiovanni J. Mechanism-based inactivation of hepatic ethoxyresorufin O-dealkylation activity by naturally occurring coumarins. Chem. Res. Toxicol. 1996; 9: 729–736
   PubMed Web of Science ®Google Scholar
• Chan J. D. Pharmacokinetic drug interactions of vinca alkaloids: summary of case reports. Pharmacother. 1998; 18: 1304–1307
   PubMed Web of Science ®Google Scholar
• Chan W. K., Delucchi A. B. Resveratrol, a red wine constituent, is a mechanism-based inactivator of cytochrome P450 3A4. Life Sci. 2000; 67: 3103–3112
   PubMed Web of Science ®Google Scholar
• Chang T. K., Chen J., Lee W. B. Differential inhibition and inactivation of human CYP1 enzymes by trans-resveratrol: evidence for mechanism-based inactivation of CYP1A2. J. Pharmacol. Exp. Ther. 2001; 299: 874–882
   PubMed Web of Science ®Google Scholar
• Chatterjee P., Franklin M. R. Human cytochrome p450 inhibition and metabolic-intermediate complex formation by goldenseal extract and its methylenedioxyphenyl components. Drug Metab. Dispos. 2003; 31: 1391–1397
   PubMed Web of Science ®Google Scholar
• Chen L., Mohr S. N., Yang C. S. Decrease of plasma and urinary oxidative metabolites of acetaminophen after consumption of watercress by human volunteers. Clin. Pharmacol. Ther. 1996; 60: 651–660
   PubMed Web of Science ®Google Scholar
• Chen Q., Ngui J. S., Doss G. A., Wang R. W., Cai X., DiNinno F. P., Blizzard T. A., Hammond M. L., Stearns R. A., Evans D. C., Baillie T. A., Tang W. Cytochrome P450 3A4‐mediated bioactivation of raloxifene: irreversible enzyme inhibition and thiol adduct formation. Chem. Res. Toxicol. 2002; 15: 907–914
   PubMed Web of Science ®Google Scholar
• Cheng C. L., Smith D. E., Carver P. L., Cox S. R., Watkins P. B., Blake D. S., Kauffman C. A., Meyer K. M., Amidon G. L., Stetson P. L. Steady-state pharmacokinetics of delavirdine in HIV-positive patients: effect on erythromycin breath test. Clin. Pharmacol. Ther. 1997; 61: 531–543
   PubMed Web of Science ®Google Scholar
• Chiba M., Nishime J. A., Lin J. H. Potent and selective inactivation of human liver microsomal cytochrome P-450 isoforms by L-754,394, an investigational human immune deficiency virus protease inhibitor. J. Pharmacol. Exp. Ther. 1995; 275: 1527–1534
   PubMed Web of Science ®Google Scholar
• Chu S., Wilson D. S., Deaton R. L., Mackenthun A. V., Eason C. N., Cavanaugh J. H. Single- and multiple-dose pharmacokinetics of clarithromycin, a new macrolide antimicrobial. J. Clin. Pharmacol. 1993; 33: 719–726
   PubMed Web of Science ®Google Scholar
• Chun Y. J., Ryu S. Y., Jeong T. C., Kim M. Y. Mechanism-based inhibition of human cytochrome P450 1A1 by rhapontigenin. Drug Metab. Dispos. 2001; 29: 389–393
   PubMed Web of Science ®Google Scholar
• Chung F. L., Morse M. A., Eklind K. I., Lewis J. Quantitation of human uptake of the anticarcinogen phenethyl isothiocyanate after a watercress meal. Cancer Epidemiol. Biomarkers Prev. 1992; 1: 383–388
   PubMed Web of Science ®Google Scholar
• Clarke S. E., Ayrton A. D., Chenery R. J. Characterization of the inhibition of P4501A2 by furafylline. Xenobiotica 1994; 24: 517–526
   PubMed Web of Science ®Google Scholar
• Colburn W. A., Di Santo A. R., Gibaldi M. Pharmacokinetics of erythromycin on repetitive dosing. J. Clin. Pharmacol. 1977; 17: 592–600
   PubMed Web of Science ®Google Scholar
• Coni E., Di Benedetto R., Di Pasquale M., Masella R., Modesti D., Mattei R., Carlini E. A. Protective effect of oleuropein, an olive oil biophenol, on low density lipoprotein oxidizability in rabbits. Lipids 2000; 35: 45–54
   PubMed Web of Science ®Google Scholar
• Cook D. L., Atkins W. M. Enhanced detoxication due to distributive catalysis and toxic thresholds: a kinetic analysis. Biochem. 1997; 36: 10801–10806
   PubMed Web of Science ®Google Scholar
• Coon M. J. Cytochrome P450: nature's most versatile biological catalyst. Annu. Rev. Pharmacol. Toxicol. 2005; 45: 1–25
   PubMed Web of Science ®Google Scholar
• Cooper D. Y., Levin S., Narasimhulu S., Rosenthal O. Photochemical action spectrum of the terminal oxidase of mixed function oxidase systems. Science 1965; 147: 400–402
   PubMed Web of Science ®Google Scholar
• Creemers G. J., Lund B., Verweij J. Topoisomerase I inhibitors: topotecan and irenotecan. Cancer Treat. Rev. 1994; 20: 73–96
   PubMed Web of Science ®Google Scholar
• Dreyer D. L., Huey P. F. Coumarins of Citrus macroptera. Phytochem. 1973; 12: 3011–3013
   Web of Science ®Google Scholar
• Decker C. J., Rashed M. S., Baillie T. A., Maltby D., Correia M. A. Oxidative metabolism of spironolactone: evidence for the involvement of electrophilic thiosteroid species in drug-mediated destruction of rat hepatic cytochrome P450. Biochem. 1989; 28: 5128–5136
   PubMed Web of Science ®Google Scholar
• Dekhuijzen P. N., Koopmans P. P. Pharmacokinetic profile of zafirlukast. Clin. Pharmacokinet. 2002; 41: 105–114
   PubMed Web of Science ®Google Scholar
• Dharmaratne H. R., Nanayakkara N. P., Khan I. A. Kavalactones from Piper methysticum, and their 13C NMR spectroscopic analyses. Phytochem. 2002; 59: 429–433
   PubMed Web of Science ®Google Scholar
• Edelson R., Berger C., Gasparro F., Jegasothy B., Heald P., Wintroub B., Vonderheid E., Knobler R., Wolff K., Plewig G., et al. Treatment of cutaneous T-cell lymphoma by extracorporeal photochemotherapy. Preliminary results. N Engl J Med. 1987; 316: 297–303
   PubMed Web of Science ®Google Scholar
• Egner P. A., Kensler T. W., Prestera T., Talalay P., Libby A. H., Joyner H. H., Curphey T. J. Regulation of phase 2 enzyme induction by oltipraz and other dithiolethiones. Carcinogenesis 1994; 15: 177–181
   PubMed Web of Science ®Google Scholar
• Eisenberg D. M., Davis R. B., Ettner S. L., Appel S., Wilkey S., Van Rompay M., Kessler R. C. Trends in alternative medicine use in the United States, 1990–1997: results of a follow-up national survey. J. Am. Med. Assoc. 1998; 280: 1569–1575
   PubMed Web of Science ®Google Scholar
• Ernest C. S., Hall S. D., Jones D. R. Mechanism-based inactivation of CYP3A by HIV protease inhibitors. J. Pharmacol. Exp. Ther. 2005; 312: 583–591
   PubMed Web of Science ®Google Scholar
• Esterbauer H., Zollner H., Lang J. Metabolism of the lipid peroxidation product 4‐hydroxynonenal by isolated hepatocytes and by liver cytosolic fractions. Biochem. J. 1985; 228: 363–373
   PubMed Web of Science ®Google Scholar
• Esterbauer H., Zollner H. Methods for determination of aldehydic lipid peroxidation products. Free Radic. Biol. Med. 1989; 7: 197–203
   PubMed Web of Science ®Google Scholar
• Evans G. H., Shand D. G. Disposition of propranolol. V. Drug accumulation and steady-state concentrations during chronic oral administration in man. Clin. Pharmacol. Ther. 1973; 14: 487–493
   PubMed Web of Science ®Google Scholar
• Faber M. S., Fuhr U. Time response of cytochrome P450 1A2 activity on cessation of heavy smoking. Clin. Pharmacol. Ther. 2004; 76: 178–184
   PubMed Web of Science ®Google Scholar
• Fabre G., Julian B., Saint-Aubert B., Joyeux H., Berger Y. Evidence for CYP3A-mediated N-deethylation of amiodarone in human liver microsomal fractions. Drug Metab. Dispos. 1993; 21: 978–985
   PubMed Web of Science ®Google Scholar
• Flora K., Hahn M., Rosen H., Benner K. Milk thistle (Silybum marianum) for the therapy of liver disease. Am J Gastroenterol. 1998; 93: 139–143
   PubMed Web of Science ®Google Scholar
• Fontana E., Dansette P. M., Poli S. M. Cytochrome p450 enzymes mechanism based inhibitors: common sub-structures and reactivity. Curr. Drug Metab. 2005; 6: 413–454
   PubMed Web of Science ®Google Scholar
• Friguet B., Stadtman E. R., Szweda L. I. Modification of glucose-6-phosphate dehydrogenase by 4-hydroxy-2-nonenal. Formation of cross-linked protein that inhibits the multicatalytic protease. J. Biol. Chem. 1994; 269: 21639–21643
   PubMed Web of Science ®Google Scholar
• Funck-Brentano C., Jacqz-Aigrain E., Leenhardt A., Roux A., Poirier J. M., Jaillon P. Influence of amiodarone on genetically determined drug metabolism in humans. Clin. Pharmacol. Ther. 1991; 50: 259–266
   PubMed Web of Science ®Google Scholar
• Funck-Brentano C., Becquemont L., Kroemer H. K., Buhl K., Knebel N. G., Eichelbaum M., Jaillon P. Variable disposition kinetics and electrocardiographic effects of flecainide during repeated dosing in humans: contribution of genetic factors, dose-dependent clearance, and interaction with amiodarone. Clin. Pharmacol. Ther. 1994; 55: 256–269
   PubMed Web of Science ®Google Scholar
• Furst S. M., Sukhai P., McClelland R. A., Uetrecht J. P. Covalent binding of carbamazepine oxidative metabolites to neutrophils. Drug Metab. Dispos. 1995; 23: 590–594
   PubMed Web of Science ®Google Scholar
• Galetin A., Burt H., Gibbons L., Houston J. B. Prediction of time-dependent CYP3A4 drug-drug interactions: impact of enzyme degradation, parallel elimination pathways, and intestinal inhibition. Drug Metab. Dispos. 2006; 34: 166–175
   PubMed Web of Science ®Google Scholar
• Gannett P. M., Iversen P., Lawson T. The mechanism of inhibition of cytochrome P450IIE1 by dihydrocapsaicin. Bioorg. Chem. 1990; 18: 185–198
   Web of Science ®Google Scholar
• Gill J., Heel R. C., Fitton A. Amiodarone. An overview of its pharmacological properties, and review of its therapeutic use in cardiac arrhythmias. Drugs 1992; 43: 69–110
   PubMed Web of Science ®Google Scholar
• Ghanbari F., Rowland-Yeo K., Bloomer J. C., Clarke S. E., Lennard M. S., Tucker G. T., Rostami-Hodjegan A. A critical evaluation of the experimental design of studies of mechanism based enzyme inhibition, with implications for in vitro-in vivo extrapolation. Curr. Drug Metab. 2006; 7: 315–334
   PubMed Web of Science ®Google Scholar
• Goosen T. C., Mills D. E., Hollenberg P. F. Effects of benzyl isothiocyanate on rat and human cytochromes P450: identification of metabolites formed by P450 2B1. J. Pharmacol. Exp. Ther. 2001; 296: 198–206
   PubMed Web of Science ®Google Scholar
• Gordon W. P., Forte A. J., McMurtry R. J., Gal J., Nelson S. D. Hepatotoxicity and pulmonary toxicity of pennyroyal oil and its constituent terpenes in the mouse. Toxicol. Appl. Pharmacol. 1982; 65: 413–424
   PubMed Web of Science ®Google Scholar
• Gorski J. C., Jones D. R., Haehner-Daniels B. D., Hamman M. A., O'Mara E. M., Hall S. D. The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin. Clin. Pharmacol. Ther. 1998; 64: 133–143
   PubMed Web of Science ®Google Scholar
• Greenblatt D. J., Preskorn S. H., Cotreau M. M., Horst W. D., Harmatz J. S. Fluoxetine impairs clearance of alprazolam but not of clonazepam. Clin. Pharmacol. Ther. 1992; 52: 479–486
   PubMed Web of Science ®Google Scholar
• Guengerich F. P. Oxidation of 17 alpha-ethynylestradiol by human liver cytochrome P-450. Mol. Pharmacol. 1988; 33: 500–508
   PubMed Web of Science ®Google Scholar
• Guengerich F. P. Mechanism-based inactivation of human liver microsomal cytochrome P‐450 IIIA4 by gestodene. Chem. Res. Toxicol. 1990; 3: 363–371
   PubMed Web of Science ®Google Scholar
• Guengerich F. P. Common and uncommon cytochrome P450 reactions related to metabolism and chemical toxicity. Chem. Res. Toxicol. 2001; 14: 611–650
   PubMed Web of Science ®Google Scholar
• Guengerich F. P. Cytochromes P450, drugs, and diseases. Mol. Interv. 2003; 3: 194–204
   PubMedGoogle Scholar
• Guengerich F. P. Cytochrome P450: what have we learned and what are the future issues?. Drug Metab. Rev. 2004; 36: 159–197
   PubMed Web of Science ®Google Scholar
• Guengerich F. P. Cytochrome P450s and other enzymes in drug metabolism and toxicity. AAPS J. 2006; 8: E101–E111
   PubMed Web of Science ®Google Scholar
• Guo Z., Smith T. J., Wang E., Eklind K. I., Chung F. L., Yang C. S. Structure-activity relationships of arylalkyl isothiocyanates for the inhibition of 4-(methylnitrosamino)-1-(3‐pyridyl)-1-butanone metabolism and the modulation of xenobiotic-metabolizing enzymes in rats and mice. Carcinogenesis 1993; 14: 1167–1173
   PubMed Web of Science ®Google Scholar
• Gurley B. J., Gardner S. F., Hubbard M. A., Williams D. K., Gentry W. B., Cui Y., Ang C. Y. Cytochrome P450 phenotypic ratios for predicting herb-drug interactions in humans. Clin. Pharmacol. Ther. 2002; 72: 276–287
   PubMed Web of Science ®Google Scholar
• Gurley B. J., Gardner S. F., Hubbard M. A., Williams D. K., Gentry W. B., Khan I. A., Shah A. In vivo effects of goldenseal, kava kava, black cohosh, and valerian on human cytochrome P450 1A2, 2D6, 2E1, and 3A4/5 phenotypes. Clin. Pharmacol. Ther. 2005; 77: 415–426
   PubMed Web of Science ®Google Scholar
• Ha-Duong N. T., Dijols S., Macherey A. C., Goldstein J. A., Dansette P. M., Mansuy D. Ticlopidine as a selective mechanism-based inhibitor of human cytochrome P450 2C19. Biochem. 2001; 40: 12112–12122
   PubMed Web of Science ®Google Scholar
• Hallifax D., Houston J. B. Binding of drugs to hepatic microsomes: comment and assessment of current prediction methodology with recommendation for improvement. Drug Metab Dispos. 2006; 34: 724–726
   PubMed Web of Science ®Google Scholar
• Halpert J., Balfour C., Miller N. E., Morgan E. T., Dunbar D., Kaminsky L. S. Isozyme selectivity of the inhibition of rat liver cytochromes P-450 by chloramphenicol in vivo. Mol. Pharmacol. 1985; 28: 290–296
   PubMed Web of Science ®Google Scholar
• Hanioka N., Ozawa S., Jinno H., Tanaka-Kagawa T., Nishimura T., Ando M., Sawada J. J. Interaction of irinotecan (CPT-11) and its active metabolite 7-ethyl-10-hydroxycamptothecin (SN-38) with human cytochrome P450 enzymes. Drug Metab. Dispos. 2002; 30: 391–396
   PubMed Web of Science ®Google Scholar
• Harleton E., Webster M., Bumpus N. N., Kent U. M., Rae J. M., Hollenberg P. F. Metabolism of N, N′, N″-triethylenethiophosphoramide by CYP2B1 and CYP2B6 results in the inactivation of both isoforms by two distinct mechanisms. J. Pharmacol. Exp. Ther. 2004; 310: 1011–1019
   PubMed Web of Science ®Google Scholar
• Harvey A. T., Preskorn S. H. Fluoxetine pharmacokinetics and effect on CYP2C19 in young and elderly volunteers. J. Clin. Psychopharmacol. 2001; 21: 161–166
   PubMed Web of Science ®Google Scholar
• He K., Falick A. M., Chen B., Nilsson F., Correia M. A. Identification of the heme adduct and an active site peptide modified during mechanism-based inactivation of rat liver cytochrome P450 2B1 by secobarbital. Chem. Res. Toxicol. 1996; 9: 614–622
   PubMed Web of Science ®Google Scholar
• He K., He Y. A., Szklarz G. D., Halpert J. R., Correia M. A. Secobarbital-mediated inactivation of cytochrome P450 2B1 and its active site mutants. Partitioning between heme and protein alkylation and epoxidation. J. Biol. Chem. 1996; 271: 25864–25872
   PubMed Web of Science ®Google Scholar
• He K., Iyer K. R., Hayes R. N., Sinz M. W., Woolf T. F., Hollenberg P. F. Inactivation of cytochrome P450 3A4 by bergamottin, a component of grapefruit juice. Chem. Res. Toxicol. 1998; 11: 252–259
   PubMed Web of Science ®Google Scholar
• He K., Woolf T. F., Hollenberg P. F. Mechanism-based inactivation of cytochrome P‐450‐3A4 by mifepristone (RU486). J. Pharmacol. Exp. Ther. 1999; 288: 791–797
   PubMed Web of Science ®Google Scholar
• Hemeryck A., Lefebvre R. A., De Vriendt C., Belpaire F. M. Paroxetine affects metoprolol pharmacokinetics and pharmacodynamics in healthy volunteers. Clin. Pharmacol. Ther. 2000; 67: 283–291
   PubMed Web of Science ®Google Scholar
• Heimark L. D., Wienkers L., Kunze K., Gibaldi M., Eddy A. C., Trager W. F., O'Reilly R. A., Goulart D. A. The mechanism of the interaction between amiodarone and warfarin in humans. Clin. Pharmacol. Ther. 1992; 51: 398–407
   PubMed Web of Science ®Google Scholar
• Hirsch A., Saccar C., McGeady S. J. Interaction between theophylline and amiodarone. Ann. Allergy 1993; 70: 68
   Google Scholar
• Hodgson E., Philpot R. M. Interaction of methylenedioxyphenyl (1,3-benzodioxole) compounds with enzymes and their effects on mammals. Drug Metab. Rev. 1974; 3: 231–301
   PubMed Web of Science ®Google Scholar
• Hollenberg P. F. Characteristics and common properties of inhibitors, inducers, and activators of CYP enzymes. Drug Metab Rev. 2002; 34: 17–35
   PubMed Web of Science ®Google Scholar
• Huitema A. D., Kerbusch T., Tibben M. M., Rodenhuis S., Beijnen J. H. Reduction of cyclophosphamide bioactivation by thioTEPA: critical sequence-dependency in high-dose chemotherapy regimens. Cancer Chemother. Pharmacol. 2000; 46: 119–127
   PubMed Web of Science ®Google Scholar
• Hutzler J. M., Steenwyk R. C., Smith E. B., Walker G. S., Wienkers L. C. Mechanism-based inactivation of cytochrome P450 2D6 by 1-[(2-ethyl-4-methyl-1H-imidazol-5-yl)methyl]-4-[4-(trifluoromethyl)-2-pyridinyl]piperazine: kinetic characterization and evidence for apoprotein adduction. Chem. Res. Toxicol. 2004; 17: 174–184
   PubMed Web of Science ®Google Scholar
• Iba M. M., Mannering G. J. NADPH- and linoleic acid hydroperoxide-induced lipid peroxidation and destruction of cytochrome P-450 in hepatic microsomes. Biochem. Pharmacol. 1987; 36: 1447–1455
   PubMed Web of Science ®Google Scholar
• Ingelman-Sundberg M. Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity. Pharmacogenom. J. 2005; 5: 6–13
   PubMed Web of Science ®Google Scholar
• Issekutz B., Lichtneckert I., Nagy H. Effect of capsaicin and histamine on heat regulation. Arch. Int. Pharmacodyn. Ther. 1950; 81: 35–46
   PubMedGoogle Scholar
• Ito K., Hallifax D., Obach R. S., Houston J. B. Impact of parallel pathways of drug elimination and multiple cytochrome P450 involvement on drug-drug interactions: CYP2D6 paradigm. Drug Metab Dispos. 2005; 33: 837–844
   PubMed Web of Science ®Google Scholar
• Ivie G. W., Holt D. L., Ivey M. C. Natural toxicants in human foods: psoralens in raw and cooked parsnip root. Science 1981; 213: 909–910
   PubMed Web of Science ®Google Scholar
• Jang G. R., Benet L. Z. Antiprogestin-mediated inactivation of cytochrome P450 3A4. Pharmacol. 1998; 56: 150–157
   PubMed Web of Science ®Google Scholar
• Jeppesen U., Gram L. F., Vistisen K., Loft S., Poulsen H. E., Brosen K. Dose-dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine. Eur. J. Clin. Pharmacol. 1996; 51: 73–78
   PubMed Web of Science ®Google Scholar
• Jhamandas K., Yaksh T. L., Harty G., Szolcsanyi J., Go V. L. Action of intrathecal capsaicin and its structural analogues on the content and release of spinal substance P: selectivity of action and relationship to analgesia. Brain Res. 1984; 306: 215–225
   PubMed Web of Science ®Google Scholar
• Jin L., Baillie T. A. Metabolism of the chemoprotective agent diallyl sulfide to glutathione conjugates in rats. Chem. Res. Toxicol. 1997; 10: 318–327
   PubMed Web of Science ®Google Scholar
• Jung-Hoffmann C., Kuhl H. Interaction with the pharmacokinetics of ethinylestradiol and progestogens contained in oral contraceptives. Contraception 1989; 40: 299–312
   PubMed Web of Science ®Google Scholar
• Jushchyshyn M. I., Kent U. M., Hollenberg P. F. The mechanism-based inactivation of human cytochrome P450 2B6 by phencyclidine. Drug Metab. Dispos. 2003; 31: 46–52
   PubMed Web of Science ®Google Scholar
• Jushchyshyn M. I., Wahlstrom J. L., Hollenberg P. F., Wienkers L. C. Mechanism of inactivation of human cytochrome P450 2B6 by phencyclidine. Drug Metab. Dispos. 2006; 34: 1523–1529
   PubMed Web of Science ®Google Scholar
• Kalgutkar A. S., Vaz A. D., Lame M. E., Henne K. R., Soglia J., Zhao S. X., Abramov Y. A., Lombardo F., Collin C., Hendsch Z. S., Hop C. E. Bioactivation of the nontricyclic antidepressant nefazodone to a reactive quinone-imine species in human liver microsomes and recombinant cytochrome P450 3A4. Drug Metab. Dispos. 2005; 33: 243–253
   PubMed Web of Science ®Google Scholar
• Kalgutkar A. S., Soglia J. R. Minimising the potential for metabolic activation in drug discovery. Expert Opin. Drug Metab. Toxicol. 2005; 1: 91–142
   PubMedGoogle Scholar
• Kalgutkar A. S., Obach R. S., Maurer T. S. Mechanism-based inactivation of cytochrome P450 enzymes: chemical mechanisms, structure-activity relationships and relationship to clinical drug-drug interactions and idiosyncratic adverse drug reactions. Curr. Drug Metab. 2007; 8: 407–447
   PubMed Web of Science ®Google Scholar
• Kapetanovic I. M., Torchin C. D., Thompson C. D., Miller T. A., McNeilly P. J., Macdonald T. L., Kupferberg H. J., Perhach J. L., Sofia R. D., Strong J. M. Potentially reactive cyclic carbamate metabolite of the antiepileptic drug felbamate produced by human liver tissue in vitro. Drug Metab. Dispos. 1998; 26: 1089–1095
   PubMed Web of Science ®Google Scholar
• Kassahun K., Skordos K., McIntosh I., Slaughter D., Doss G. A., Baillie T. A., Yost G. S. Zafirlukast metabolism by cytochrome P450 3A4 produces an electrophilic alpha, beta-unsaturated iminium species that results in the selective mechanism-based inactivation of the enzyme. Chem. Res. Toxicol. 2005; 18: 1427–1437
   PubMed Web of Science ®Google Scholar
• Kaul S., Shukla U. A., Barbhaiya R. H. Nonlinear pharmacokinetics of nefazodone after escalating single and multiple oral doses. J. Clin. Pharmacol. 1995; 35: 830–839
   PubMed Web of Science ®Google Scholar
• Keledjian J., Duffield P. H., Jamieson D. D., Lidgard R. O., Duffield A. M. Uptake into mouse brain of four compounds present in the psychoactive beverage kava. J. Pharm. Sci. 1988; 77: 1003–1006
   PubMed Web of Science ®Google Scholar
• Kensler T. W., Egner P. A., Dolan P. M., Groopman J. D., Roebuck B. D. Mechanism of protection against aflatoxin tumorigenicity in rats fed 5-(2-pyrazinyl)-4-methyl-1,2-dithiol-3-thione (oltipraz) and related 1,2-dithiol-3-thiones and 1,2-dithiol-3-ones. Cancer Res. 1987; 47: 4271–4277
   PubMed Web of Science ®Google Scholar
• Kensler T. W., Groopman J. D., Eaton D. L., Curphey T. J., Roebuck B. D. Potent inhibition of aflatoxin-induced hepatic tumorigenesis by the monofunctional enzyme inducer 1,2‐dithiole-3-thione. Carcinogenesis 1992; 13: 95–100
   PubMed Web of Science ®Google Scholar
• Kent U. M., Roberts E. S., Chun J., Hodge K., Juncaj J., Hollenberg P. F. Inactivation of cytochrome P450 2E1 by tert-butylisothiocyanate. Chem. Res. Toxicol. 1998; 11: 1154–1161
   PubMed Web of Science ®Google Scholar
• Kent U. M., Juschyshyn M. I., Hollenberg P. F. Mechanism-based inactivators as probes of cytochrome P450 structure and function. Curr. Drug Metab. 2001; 2: 215–243
   PubMed Web of Science ®Google Scholar
• Kent U. M., Mills D. E., Rajnarayanan R. V., Alworth W. L., Hollenberg P. F. Effect of 17-alpha-ethynylestradiol on activities of cytochrome P450 2B (P450 2B) enzymes: characterization of inactivation of P450s 2B1 and 2B6 and identification of metabolites. J. Pharmacol. Exp. Ther. 2002; 300: 549–558
   PubMed Web of Science ®Google Scholar
• Kent U. M., Aviram M., Rosenblat M., Hollenberg P. F. The licorice root derived isoflavan glabridin inhibits the activities of human cytochrome P450S 3A4, 2B6, and 2C9. Drug Metab. Dispos. 2002; 30: 709–715
   PubMed Web of Science ®Google Scholar
• Khan K. K., He Y. Q., Domanski T. L., Halpert J. R. Midazolam oxidation by cytochrome P450 3A4 and active-site mutants: an evaluation of multiple binding sites and of the metabolic pathway that leads to enzyme inactivation. Mol. Pharmacol. 2002a; 61: 495–506
   PubMed Web of Science ®Google Scholar
• Khan K. K., He Y. Q., Correia M. A., Halpert J. R. Differential oxidation of mifepristone by cytochromes P450 3A4 and 3A5: selective inactivation of P450 3A4. Drug Metab. Dispos. 2002b; 30: 985–990
   PubMed Web of Science ®Google Scholar
• Khojasteh-Bakht S. C., Koenigs L. L., Peter R. M., Trager W. F., Nelson S. D. (R)‐(+)‐Menthofuran is a potent, mechanism-based inactivator of human liver cytochrome P450 2A6. Drug Metab. Dispos. 1998; 26: 701–704
   PubMed Web of Science ®Google Scholar
• Knudsen J. B., Bastain W., Sefton C. M., Allen J. G., Dickinson J. P. Pharmacokinetics of ticlopidine during chronic oral administration to healthy volunteers and its effects on antipyrine pharmacokinetics. Xenobiotica 1992; 22: 579–589
   PubMed Web of Science ®Google Scholar
• Kobayashi Y., Sridar C., Kent U. M., Puppali S. G., Rimoldi J. M., Zhang H., Waskell L., Hollenberg P. F. Structure-activity relationship and elucidation of the determinant factor(s) responsible for the mechanism-based inactivation of cytochrome P450 2B6 by substituted phenyl diaziridines. Drug Metab Dispos. 2006; 34: 2102–2110
   PubMed Web of Science ®Google Scholar
• Koenigs L. L., Trager W. F. Mechanism-based inactivation of P450 2A6 by furanocoumarins. Biochem. 1998; 37: 10047–10061
   PubMed Web of Science ®Google Scholar
• Koenigs L. L., Trager W. F. Mechanism-based inactivation of cytochrome P450 2B1 by 8‐methoxypsoralen and several other furanocoumarins. Biochem. 1998; 37: 13184–13193
   PubMed Web of Science ®Google Scholar
• Koudriakova T., Iatsimirskaia E., Utkin I., Gangl E., Vouros P., Storozhuk E., Orza D., Marinina J., Gerber N. Metabolism of the human immunodeficiency virus protease inhibitors indinavir and ritonavir by human intestinal microsomes and expressed cytochrome P4503A4/3A5: mechanism-based inactivation of cytochrome P4503A by ritonavir. Drug Metab Dispos. 1998; 26: 552–561
   PubMed Web of Science ®Google Scholar
• Kraner J. C., Morgan E. T., Halpert J. R. Selective suppression of rat hepatic cytochrome P450 2C11 by chloramphenicol. J. Pharmacol. Exp. Ther. 1994; 270: 1367–1372
   PubMed Web of Science ®Google Scholar
• Kroemer H. K., Echizen H., Heidemann H., Eichelbaum M. Predictability of the in vivo metabolism of verapamil from in vitro data: contribution of individual metabolic pathways and stereoselective aspects. J. Pharmacol. Exp. Ther. 1992; 260: 1052–1057
   PubMed Web of Science ®Google Scholar
• Kuehl P., Zhang J., Lin Y., Lamba J., Assem M., Schuetz J., Watkins P. B., Daly A., Wrighton S. A., Hall S. D., Maurel P., Relling M., Brimer C., Yasuda K., Venkataramanan R., Strom S., Thummel K., Boguski M. S., Schuetz E. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat. Genet. 2001; 27: 383–391
   PubMed Web of Science ®Google Scholar
• Kunze K. L., Trager W. F. Isoform-selective mechanism-based inhibition of human cytochrome P450 1A2 by furafylline. Chem. Res. Toxicol. 1993; 6: 649–656
   PubMed Web of Science ®Google Scholar
• Kuo C. L., Vaz A. D., Coon M. J. Metabolic activation of trans-4-hydroxy-2-nonenal, a toxic product of membrane lipid peroxidation and inhibitor of P450 cytochromes. J. Biol. Chem. 1997; 272: 22611–22616
   PubMed Web of Science ®Google Scholar
• Lakhanpal S., Donehower R. C., Rowinsky E. K. Phase II study of 4-ipomeanol, a naturally occurring alkylating furan, in patients with advanced hepatocellular carcinoma. Invest. New Drugs. 2001; 19: 69–76
   PubMed Web of Science ®Google Scholar
• Laganiere S., Davies R. F., Carignan G., Foris K., Goernert L., Carrier K., Pereira C., McGilveray I. Pharmacokinetic and pharmacodynamic interactions between diltiazem and quinidine. Clin. Pharmacol. Ther. 1996; 60: 255–264
   PubMed Web of Science ®Google Scholar
• Langouet S., Furge L. L., Kerriguy N., Nakamura K., Guillouzo A., Guengerich F.P. Inhibition of human cytochrome P450 enzymes by 1,2-dithiole-3-thione, oltipraz and its derivatives, and sulforaphane. Chem. Res. Toxicol. 2000; 13: 245–252
   PubMed Web of Science ®Google Scholar
• Leclercq I., Desager J. P., Horsmans Y. Inhibition of chlorzoxazone metabolism, a clinical probe for CYP2E1, by a single ingestion of watercress. Clin. Pharmacol. Ther. 1998; 64: 144–149
   PubMed Web of Science ®Google Scholar
• Lemberger L., Rowe H., Bosomworth J. C., Tenbarge J. B., Bergstrom R. F. The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam. Clin. Pharmacol. Ther. 1988; 43: 412–419
   PubMed Web of Science ®Google Scholar
• Letteron P., Descatoire V., Larrey D., Tinel M., Geneve J., Pessayre D. Inactivation and induction of cytochrome P-450 by various psoralen derivatives in rats. J. Pharmacol. Exp. Ther. 1986; 238: 685–692
   PubMed Web of Science ®Google Scholar
• Licad-Coles E., He K., Yin H., Correia M. A. Cytochrome P450 2C11: Escherichia coli expression, purification, functional characterization, and mechanism-based inactivation of the enzyme. Arch. Biochem. Biophys. 1997; 338: 35–42
   PubMed Web of Science ®Google Scholar
• Lillibridge J. H., Amore B. M., Slattery J. T., Kalhorn T. F., Nelson S. D., Finnell R. H., Bennett G. D. Protein-reactive metabolites of carbamazepine in mouse liver microsomes. Drug Metab. Dispos. 1996; 24: 509–514
   PubMed Web of Science ®Google Scholar
• Lin H. L., Kent U. M., Hollenberg P. F. The grapefruit juice effect is not limited to cytochrome P450 (P450) 3A4: evidence for bergamottin-dependent inactivation, heme destruction, and covalent binding to protein in P450s 2B6 and 3A5. J. Pharmacol. Exp. Ther. 2005; 313: 154–164
   PubMed Web of Science ®Google Scholar
• López-Garcia M. P., Dansette P. M., Mansuy D. Thiophene derivatives as new mechanism-based inhibitors of cytochromes P-450: inactivation of yeast-expressed human liver cytochrome P-450 2C9 by tienilic acid. Biochemistry 1994; 33: 166–175
   PubMed Web of Science ®Google Scholar
• Lu P., Schrag M. L., Slaughter D. E., Raab C. E., Shou M., Rodrigues A. D. Mechanism-based inhibition of human liver microsomal cytochrome P450 1A2 by zileuton, a 5-lipoxygenase inhibitor. Drug Metab. Dispos. 2003; 31: 1352–1360
   PubMed Web of Science ®Google Scholar
• Ma Q., Okusanya O. O., Smith P. F., Dicenzo R., Slish J. C., Catanzaro L. M., Forrest A., Morse G. D. Pharmacokinetic drug interactions with non-nucleoside reverse transcriptase inhibitors. Expert Opin. Drug Metab. Toxicol. 2005; 1: 473–485
   PubMedGoogle Scholar
• Macdonald T. L., Gutheim W. G., Martin R. B., Guengerich F. P. Oxidation of substituted N, N-dimethylanilines by cytochrome P-450: estimation of the effective oxidation-reduction potential of cytochrome P-450. Biochemistry 1989; 28: 2071–2017
   PubMed Web of Science ®Google Scholar
• Madden S., Maggs J. L., Park B. K. Bioactivation of carbamazepine in the rat in vivo. Evidence for the formation of reactive arene oxide(s). Drug Metab. Dispos. 1996; 24: 469–479
   PubMed Web of Science ®Google Scholar
• Madeira M., Levine M., Chang T. K. H, Mirfazaelian A., Bellward G. D. The effect of cimetidine on dextromethorphan o-demethylase activity of human liver microsomes and recombinant cyp2d6. Drug Metab. Dispos. 2004; 32: 460–467
   PubMed Web of Science ®Google Scholar
• Masubuchi Y., Horie T. Mechanism-based inactivation of cytochrome P450s 1A2 and 3A4 by dihydralazine in human liver microsomes. Chem. Res. Toxicol. 1999; 12: 1028–1032
   PubMed Web of Science ®Google Scholar
• Masubuchi Y., Nakano T., Ose A., Horie T. Differential selectivity in carbamazepine-induced inactivation of cytochrome P450 enzymes in rat and human liver. Arch. Toxicol. 2001; 75: 538–543
   PubMed Web of Science ®Google Scholar
• Masubuchi Y., Ose A., Horie T. Mechanism-based inactivation of CYP2C11 by diclofenac. Drug Metab. Dispos. 2001; 29: 1190–1195
   PubMed Web of Science ®Google Scholar
• Masubuchi Y., Ose A., Horie T. Diclofenac-induced inactivation of CYP3A4 and its stimulation by quinidine. Drug Metab. Dispos. 2002; 30: 1143–1148
   PubMed Web of Science ®Google Scholar
• Mathews J. M., Etheridge A. S., Black S. R. Inhibition of human cytochrome P450 activities by kava extract and kavalactones. Drug Metab. Dispos. 2002; 30: 1153–1157
   PubMed Web of Science ®Google Scholar
• Mayhew B. S., Jones D. R., Hall S. D. An in vitro model for predicting in vivo inhibition of cytochrome P450 3A4 by metabolic intermediate complex formation. Drug Metab. Dispos. 2000; 28: 1031–1037
   PubMed Web of Science ®Google Scholar
• McGinnity D. F., Berry A. J., Kenny J. R., Grime K., Riley R. J. Evaluation of time-dependent cytochrome P450 inhibition using cultured human hepatocytes. Drug Metab. Dispos. 2006; 34: 1291–1300
   PubMed Web of Science ®Google Scholar
• McTavish D., Sorkin E. M. Verapamil. An updated review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension. Drugs 1989; 38: 19–76
   PubMed Web of Science ®Google Scholar
• Michos N., Zulliger H. W., Barkworth M. F., Johnson K. J., Rehm K. D., Toberich H., Klein G. Suprofen sustained release kinetics in healthy male volunteers. 1st communication: a single dose open crossover bioavailability study of suprofen sustained release tablets versus capsules. Arzneimittelforschung 1986; 36: 941–948
   PubMed Web of Science ®Google Scholar
• Miller R. R., Porter J., Greenblatt D. J. Clinical importance of the interaction of phenytoin and isoniazid: a report from the Boston Collaborative Drug Surveillance Program. Chest 1979; 75: 356–358
   PubMed Web of Science ®Google Scholar
• Miller D. D., Sawyer J. B., Duffy J. P. Cimetidine's effect on steady-state serum nortriptyline concentrations. Drug Intell. Clin. Pharm. 1983; 17: 904–905
   PubMedGoogle Scholar
• Miller J. W., Skerjanec A., Knadler M. P., Ghosh A., Allerheiligen S. R. Divergent effects of raloxifene HCI on the pharmacokinetics and pharmacodynamics of warfarin. Pharm. Res. 2001; 18: 1024–1028
   PubMed Web of Science ®Google Scholar
• Millward M. J., Cantwell B. M., Lien E. A., Carmichael J., Harris A.L. Intermittent high-dose tamoxifen as a potential modifier of multidrug resistance. Eur. J. Cancer 1992; 28A: 805–810
   PubMed Web of Science ®Google Scholar
• Mitscher L. A., Drake S., Gollapudi S. R., Harris J. A., Shankel D. M. Isolation and identification of higher plant agents active in antimutagenic assay systems: Glycyrrhiza glabra. Basic Life Sci. 1986; 39: 153–165
   PubMedGoogle Scholar
• Modly C. E., Das M., Don P. S., Marcelo C. L., Mukhtar H., Bickers D. R. Capsaicin as an in vitro inhibitor of benzo(a)pyrene metabolism and its DNA binding in human and murine keratinocytes. Drug Metab. Dispos. 1986; 14: 413–416
   PubMed Web of Science ®Google Scholar
• Monahan B. P., Ferguson C. L., Killeavy E. S., Lloyd B. K., Troy J., Cantilena L. R. Torsades de pointes occurring in association with terfenadine use. J. Am. Med. Assoc. 1990; 264: 2788–2790
   PubMed Web of Science ®Google Scholar
• Montamat S. C., Abernethy D. R. Calcium antagonists in geriatric patients: diltiazem in elderly persons with hypertension. Clin. Pharmacol. Ther. 1989; 45: 682–691
   PubMed Web of Science ®Google Scholar
• Mori Y., Sakai Y., Kuroda N., Yokoya F., Toyoshi K., Horie M., Baba S. Further structural analysis of urinary metabolites of suprofen in the rat. Drug Metab. Dispos. 1984; 12: 767–771
   PubMed Web of Science ®Google Scholar
• Munns A. J., De Voss J. J., Hooper W. D., Dickinson R. G., Gillam E. M. Bioactivation of phenytoin by human cytochrome P450: characterization of the mechanism and targets of covalent adduct formation. Chem. Res. Toxicol. 1997; 10: 1049–1058
   PubMed Web of Science ®Google Scholar
• Murray M., Reidy G. F. In vitro formation of an inhibitory complex between an isosafrole metabolite and rat hepatic cytochrome P-450 PB-B. Drug Metab. Dispos. 1989; 17: 449–454
   PubMed Web of Science ®Google Scholar
• Murray M., Reidy G. F. Selectivity in the inhibition of mammalian cytochromes P-450 by chemical agents. Pharmacol. Rev. 1990; 42: 85–101
   PubMed Web of Science ®Google Scholar
• Nakajima M., Yoshida R., Shimada N., Yamazaki H., Yokoi T. Inhibition and inactivation of human cytochrome P450 isoforms by phenethyl isothiocyanate. Drug Metab. Dispos. 2001; 29: 1110–1113
   PubMed Web of Science ®Google Scholar
• Narimatsu S., Arai T., Watanabe T., Masubuchi Y., Horie T., Suzuki T., Ishikawa T., Tsutsui M., Kumagai Y., Cho A. K. Covalent binding of a reactive metabolite derived from propranolol and its active metabolite 4-hydroxypropranolol to hepatic microsomal proteins of the rat. Chem. Res. Toxicol. 1997; 10: 289–295
   PubMed Web of Science ®Google Scholar
• Narimatsu S., Arai T., Masubuchi Y., Horie T., Hosokawa M., Ueno K., Kataoka H., Yamamoto S., Ishikawa T., Cho A. K. Inactivation of rat cytochrome P450 2D enzyme by a further metabolite of 4-hydroxypropranolol, the major and active metabolite of propranolol. Biol. Pharm. Bull. 2001; 24: 988–994
   PubMed Web of Science ®Google Scholar
• Nicolau D. P., Uber W. E., Crumbley A. J., Strange C. Amiodarone-cyclosporine interaction in a heart transplant patient. J. Heart Lung Transplant 1992; 11: 564–568
   PubMed Web of Science ®Google Scholar
• Nolan P. E., Marcus F. I., Hoyer G. L., Bliss M., Gear K. Pharmacokinetic interaction between intravenous phenytoin and amiodarone in healthy volunteers. Clin. Pharmacol. Ther. 1989; 46: 43–50
   PubMed Web of Science ®Google Scholar
• Obach R. S., Walsky R. L., Venkatakrishnan K., Gaman E. A., Houston J. B., Tremaine L. M. The utility of in vitro cytochrome P450 inhibition data in the prediction of drug-drug interactions. J. Pharmacol. Exp. Ther. 2006; 316: 336–348
   PubMed Web of Science ®Google Scholar
• Ochs H. R., Greenblatt D. J., Roberts G. M., Dengler H. J. Diazepam interaction with antituberculosis drugs. Clin. Pharmacol. Ther. 1981; 29: 671–678
   PubMed Web of Science ®Google Scholar
• Ochs H. R., Greenblatt D. J., Knuchel M. Differential effect of isoniazid on triazolam oxidation and oxazepam conjugation. Br. J. Clin. Pharmacol. 1983; 16: 743–746
   PubMed Web of Science ®Google Scholar
• O'Donnell J. P., Dalvie D. K., Kalgutkar A. S., Obach R. S. Mechanism-based inactivation of human recombinant P450 2C9 by the nonsteroidal anti-inflammatory drug suprofen. Drug Metab. Dispos. 2003; 31: 1369–1377
   PubMed Web of Science ®Google Scholar
• Offman E. M., Freeman D. J., Dresser G. K., Munoz C., Bend J. R., Bailey D. G. Red wine‐cisapride interaction: comparison with grapefruit juice. Clin. Pharmacol. Ther. 2001; 70: 17–23
   PubMed Web of Science ®Google Scholar
• Ogilvie B. W., Zhang D., Li W., Rodrigues A. D., Gipson A. E., Holsapple J., Toren P., Parkinson A. Glucuronidation converts gemfibrozil to a potent, metabolism-dependent inhibitor of CYP2C8: implications for drug-drug interactions. Drug Metab. Dispos. 2006; 34: 191–197
   PubMed Web of Science ®Google Scholar
• Ohno Y., Hisaka A., Suzuki H. General framework for the quantitative prediction of CYP3A4-mediated oral drug interactions based on the AUC increase by coadministration of standard drugs. Clin Pharmacokinet. 2007; 46: 681–696
   PubMed Web of Science ®Google Scholar
• Ohyama K., Nakajima M., Suzuki M., Shimada N., Yamazaki H., Yokoi T. Inhibitory effects of amiodarone and its N-deethylated metabolite on human cytochrome P450 activities: prediction of in vivo drug interactions. Br. J. Clin. Pharmacol. 2000; 49: 244–253
   PubMed Web of Science ®Google Scholar
• O'Reilly R. A., Trager W. F., Rettie A. E., Goulart D. A. Interaction of amiodarone with racemic warfarin and its separated enantiomorphs in humans. Clin. Pharmacol. Ther. 1987; 42: 290–294
   PubMed Web of Science ®Google Scholar
• Ortiz de Montellano P. R., Mathews J. M. Autocatalytic alkylation of the cytochrome P‐450 prosthetic haem group by 1-aminobenzotriazole. Isolation of an NN-bridged benzyne-protoporphyrin IX adduct. Biochem. J. 1981; 195: 761–764
   PubMed Web of Science ®Google Scholar
• Ortiz De Montellano P. R. Cytochrome P450: Structure, Mechanism, and Biochemistry2^nd, Paul R. Ortiz De Montellano. Plenum Press, New York 1995
   Google Scholar
• Ortiz De Montellano P. R. Cytochrome P450: Structure, Mechanism, and Biochemistry2^nd, Paul R. Ortiz De Montellano. Kluwer Academic/Plenum Publishers, New York 2005
   Google Scholar
• Paddack G. L., Wahl R. C., Holman R. E., Schorr W. J., Lacher J. W. Acute renal failure associated with ticrynafen. J. Am. Med. Assoc. 1980; 243: 764–765
   Web of Science ®Google Scholar
• Pathak M. A., Daniels F., Fitzpatrick T. B. The presently known distribution of furocoumarins (psoralens) in plants. J. Invest. Dermatol. 1962; 39: 225–239
   PubMed Web of Science ®Google Scholar
• Pellock J. M., Brodie M. J. Felbamate: 1997 update. Epilepsia 1997; 38: 1261–1264
   PubMed Web of Science ®Google Scholar
• Pirisi F. M., Cabras P., Cao C. F., Migliorini M., Muggelli M. Phenolic compounds in virgin olive oil. 2. Reappraisal of the extraction, HPLC separation, and quantification procedures. J. Agric. Food Chem. 2000; 48: 1191–1196
   PubMed Web of Science ®Google Scholar
• Poet T. S., Brendel K., Halpert J. R. Inactivation of cytochromes P450 2B protects against cocaine-mediated toxicity in rat liver slices. Toxicol. Appl. Pharmacol. 1994; 126: 26–32
   PubMed Web of Science ®Google Scholar
• Polasek T. M., Elliot D. J., Lewis B. C., Miners J. O. Mechanism-based inactivation of human cytochrome P4502C8 by drugs in vitro. J. Pharmacol. Exp. Ther. 2004; 311: 996–1007
   PubMed Web of Science ®Google Scholar
• Polasek T. M., Miners J. O. Quantitative prediction of macrolide drug-drug interaction potential from in vitro studies using testosterone as the human cytochrome P4503A substrate. Eur. J. Clin. Pharmacol. 2006; 62: 203–208
   PubMed Web of Science ®Google Scholar
• Potkin S. G., Thyrum P. T., Alva G., Carreon D., Yeh C., Kalali A., Arvanitis L. A, the Pharmacokinetic Study Group. Effect of fluoxetine and imipramine on the pharmacokinetics and tolerability of the antipsychotic quetiapine. J. Clin. Psychopharmacol. 2002; 22: 174–182
   PubMed Web of Science ®Google Scholar
• Premdas P. D., Bowers R. J., Forkert P. G. Inactivation of hepatic CYP2E1 by an epoxide of diallyl sulfone. J. Pharmacol. Exp. Ther. 2000; 293: 1112–1120
   PubMed Web of Science ®Google Scholar
• Racha J.K., Rettie A.E., Kunze K.L. Mechanism-based inactivation of human cytochrome P450 1A2 by furafylline: detection of a 1:1 adduct to protein and evidence for the formation of a novel imidazomethide intermediate. Biochem. 1998; 37: 7407–7419
   PubMed Web of Science ®Google Scholar
• Reilly C. A., Ehlhardt W. J., Jackson D. A., Kulanthaivel P., Mutlib A. E., Espina R. J., Moody D. E., Crouch D. J., Yost G. S. Metabolism of capsaicin by cytochrome P450 produces novel dehydrogenated metabolites and decreases cytotoxicity to lung and liver cells. Chem Res Toxicol. 2003; 16: 336–349
   PubMed Web of Science ®Google Scholar
• Reimann I. W., Klotz U., Siems B., Frolich J. Cimetidine increases steady state plasma levels of propranolol. Br. J. Clin. Pharmacol. 1981; 12: 785–790
   PubMed Web of Science ®Google Scholar
• Rendic S. Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002; 34: 83–448
   PubMed Web of Science ®Google Scholar
• Richter T., Murdter T. E., Heinkele G., Pleiss J., Tatzel S., Schwab M., Eichelbaum M., Zanger U. M. Potent mechanism-based inhibition of human CYP2B6 by clopidogrel and ticlopidine. J. Pharmacol. Exp. Ther. 2004; 308: 189–197
   PubMed Web of Science ®Google Scholar
• Richter T., Schwab M., Eichelbaum M., Zanger U.M. Inhibition of human CYP2B6 by N, N′, N”triethylenethiophosphoramide is irreversible and mechanism-based. Biochem. Pharmacol. 2005; 69: 517–524
   PubMed Web of Science ®Google Scholar
• Ritchie L. D., Grant S. M. Tamoxifen-warfarin interaction: the Aberdeen hospitals drug file. Br. Med. J. 1989; 298: 1253
   PubMed Web of Science ®Google Scholar
• Rosenblat M., Belinky P., Vaya J., Levy R., Hayek T., Coleman R., Merchav S., Aviram M. Macrophage enrichment with the isoflavan glabridin inhibits NADPH oxidase-induced cell-mediated oxidation of low density lipoprotein. A possible role for protein kinase C. J. Biol. Chem. 1999; 274: 13790–13799
   PubMed Web of Science ®Google Scholar
• Rota C., Barr D. P., Martin M. V., Guengerich F. P., Tomasi A., Mason R. P. Detection of free radicals produced from the reaction of cytochrome P-450 with linoleic acid hydroperoxide. Biochem. J. 1997; 328: 565–571
   PubMed Web of Science ®Google Scholar
• Ruze P. Kava-induced dermopathy: a niacin deficiency?. Lancet 1990; 335: 1442–1445
   PubMed Web of Science ®Google Scholar
• Samigun, Mulyono, Santoso B. Lowering of theophylline clearance by isoniazid in slow and rapid acetylators. Br. J. Clin. Pharmacol. 1990; 29: 570–573
   PubMed Web of Science ®Google Scholar
• Sahali-Sahly Y., Balani S. K., Lin J. H., Baillie T. A. In vitro studies on the metabolic activation of the furanopyridine L-754,394, a highly potent and selective mechanism-based inhibitor of cytochrome P450 3A4. Chem. Res. Toxicol. 1996; 9: 1007–1012
   PubMed Web of Science ®Google Scholar
• Schaefer W. H., Harris T. M., Guengerich F. P. Characterization of the enzymatic and nonenzymatic peroxidative degradation of iron porphyrins and cytochrome P-450 heme. Biochem. 1985; 24: 3254–3263
   PubMed Web of Science ®Google Scholar
• Schauenstein E., Esterbauer H. Formation and properties of reactive aldehydes. Ciba. Found. Symp. 1978; 67: 225–244
   PubMedGoogle Scholar
• Schellens J. H., van der Wart J. H., Brugman M., Breimer D. D. Influence of enzyme induction and inhibition on the oxidation of nifedipine, sparteine, mephenytoin and antipyrine in humans as assessed by a “cocktail” study design. J. Pharmacol. Exp. Ther. 1989; 249: 638–645
   PubMed Web of Science ®Google Scholar
• Schmiedlin-Ren P., Edwards D. J., Fitzsimmons M. E., He K., Lown K. S., Woster P. M., Rahman A., Thummel K. E., Fisher J. M., Hollenberg P. F., Watkins P. B. Mechanisms of enhanced oral availability of CYP3A4 substrates by grapefruit constituents. Decreased enterocyte CYP3A4 concentration and mechanism-based inactivation by furanocoumarins. Drug Metab. Dispos. 1997; 25: 1228–1233
   PubMed Web of Science ®Google Scholar
• Sellers E. M., Ramamoorthy Y., Zeman M. V., Djordjevic M. V., Tyndale R. F. The effect of methoxsalen on nicotine and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) metabolism in vivo. Nicotine Tob. Res. 2003; 5: 891–899
   PubMed Web of Science ®Google Scholar
• Sharma U., Roberts E. S., Kent U. M., Owens S. M., Hollenberg P. F. Metabolic inactivation of cytochrome P4502B1 by phencyclidine: immunochemical and radiochemical analyses of the protective effects of glutathione. Drug Metab. Dispos. 1997; 25: 243–250
   PubMed Web of Science ®Google Scholar
• Sindrup S. H., Brøsen K., Gram L. F., Hallas J., Skjelbo E., Allen A., Allen G. D., Cooper S. M., Mellows G., Tasker T. C., et al. The relationship between paroxetine and the sparteine oxidation polymorphism. Clin Pharmacol Ther. 1992; 51: 278–287
   PubMed Web of Science ®Google Scholar
• Silverman R. B. Mechanism-based enzyme inactivators. Methods Enzymol. 1995; 249: 240–283
   PubMed Web of Science ®Google Scholar
• Smith T. J., Guo Z., Li C., Ning S. M., Thomas P. E., Yang C. S. Mechanisms of inhibition of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone bioactivation in mouse by dietary phenethyl isothiocyanate. Cancer Res. 1993; 53: 3276–3282
   PubMed Web of Science ®Google Scholar
• Snyder K. R., Sparano N., Malinowski J. M. Raloxifene hydrochloride. Am. J. Health Syst. Pharm. 2000; 57: 1669–1675
   PubMed Web of Science ®Google Scholar
• Sofowora G. G., Choo E. F., Mayo G., Shyr Y., Wilkinson G. R. In vivo inhibition of human CYP1A2 activity by oltipraz. Cancer Chemother. Pharmacol. 2001; 47: 505–510
   PubMed Web of Science ®Google Scholar
• Sridar C., Kent U. M., Notley L. M., Gillam E. M., Hollenberg P. F. Effect of tamoxifen on the enzymatic activity of human cytochrome CYP2B6. J. Pharmacol. Exp. Ther. 2002; 301: 945–952
   PubMed Web of Science ®Google Scholar
• Sridar C., Goosen T. C., Kent U. M., Williams J. A., Hollenberg P. F. Silybin inactivates cytochromes P450 3A4 and 2C9 and inhibits major hepatic glucuronosyltransferases. Drug Metab. Dispos. 2004; 32: 587–594
   PubMed Web of Science ®Google Scholar
• Sridar C., Kobayashi Y., Brevig H., Kent U. M., Puppali S. G., Rimoldi J. M., Hollenberg P. F. Synthesis of substituted phenyl diaziridines and characterization as mechanism-based inactivators of human cytochrome P450 2B6. Drug Metab Dispos. 2006; 34: 1849–1855
   PubMed Web of Science ®Google Scholar
• Steiner E., Spina E. Differences in the inhibitory effect of cimetidine on desipramine metabolism between rapid and slow debrisoquin hydroxylators. Clin. Pharmacol. Ther. 1987; 42: 278–282
   PubMed Web of Science ®Google Scholar
• Stupans I., Murray M., Kirlich A., Tuck K. L., Hayball P. J. Inactivation of cytochrome P450 by the food-derived complex phenol oleuropein. Fd. Chem. Toxicol. 2001; 39: 1119–1124
   PubMed Web of Science ®Google Scholar
• Steward D. J., Haining R. L., Henne K. R., Davis G., Rushmore T. H., Trager W. F., Rettie A. E. Genetic association between sensitivity to warfarin and expression of CYP2C9*3. Pharmacogenetics 1997; 7: 361–367
   PubMedGoogle Scholar
• Su T., Bao Z., Zhang Q. Y., Smith T. J., Hong J. Y., Ding X. Human cytochrome P450 CYP2A13: predominant expression in the respiratory tract and its high efficiency metabolic activation of a tobacco-specific carcinogen, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone. Cancer Res. 2000; 60: 5074–5079
   PubMed Web of Science ®Google Scholar
• Sweetman S. C., Blake P. S., McGlashan J. M., Parsons A.V. Martindale: The Extra Pharmacopeia33rd. Pharmaceutical Press, London 2002; 1101
   Google Scholar
• Szweda L. I., Uchida K., Tsai L., Stadtman E. R. Inactivation of glucose-6-phosphate dehydrogenase by 4-hydroxy-2-nonenal. Selective modification of an active-site lysine. J. Biol. Chem. 1993; 268: 3342–3347
   PubMed Web of Science ®Google Scholar
• Thomassen D., Slattery J. T., Nelson S. D. Contribution of menthofuran to the hepatotoxicity of pulegone: assessment based on matched area under the curve and on matched time course. J. Pharmacol. Exp. Ther. 1988; 244: 825–829
   PubMed Web of Science ®Google Scholar
• Thompson G. A. The Regulation of Membrane Lipid Metabolism, G.A. Thomspon. CRC Press, Boca Raton, Florida 1980; 1–17
   Google Scholar
• Toda N., Usui H., Nishino N., Fujiwara M. Cardiovascular effects of capsaicin in dogs and rabbits. J. Pharmacol. Exp. Ther. 1972; 181: 512–521
   PubMed Web of Science ®Google Scholar
• Uchida K., Stadtman E. R. Covalent attachment of 4-hydroxynonenal to glyceraldehyde-3‐phosphate dehydrogenase. A possible involvement of intra- and intermolecular cross-linking reaction. J. Biol. Chem. 1993; 268: 6388–6393
   PubMed Web of Science ®Google Scholar
• Usia T., Watabe T., Kadota S., Tezuka Y. Mechanism-based inhibition of CYP3A4 by constituents of Zingiber aromaticum. Biol. Pharm. Bull. 2005; 28: 495–499
   PubMed Web of Science ®Google Scholar
• Usia T., Watabe T., Kadota S., Tezuka Y. Metabolite-cytochrome P450 complex formation by methylenedioxyphenyl lignans of Piper cubeba: mechanism-based inhibition. Life Sci. 2005; 76: 2381–2391
   PubMed Web of Science ®Google Scholar
• Vaccaro E., Giorgi M., Longo V., Mengozzi G., Gervasi P. G. Inhibition of cytochrome p450 enzymes by enrofloxacin in the sea bass (Dicentrarchus labrax). Aquat. Toxicol. 2003; 62: 27–33
   PubMed Web of Science ®Google Scholar
• Vanden Bossche H., Koymans L., Moereels H. P450 inhibitors of use in medical treatment: focus on mechanisms of action. Pharmacol Ther. 1995; 67: 79–100
   PubMed Web of Science ®Google Scholar
• van Erp N. P., Baker S. D., Zhao M., Rudek M. A., Guchelaar H. J., Nortier J. W., Sparreboom A., Gelderblom H. Effect of milk thistle (Silybum marianum) on the pharmacokinetics of irinotecan. Clin. Cancer Res. 2005; 11: 7800–7806
   PubMed Web of Science ®Google Scholar
• Vaya J., Belinky P. A., Aviram M. Antioxidant constituents from licorice roots: isolation, structure elucidation and antioxidative capacity toward LDL oxidation. Free Radic. Biol. Med. 1997; 23: 302–313
   PubMed Web of Science ®Google Scholar
• Venkatakrishnan K., Obach R. S. In vitro-in vivo extrapolation of CYP2D6 inactivation by paroxetine: prediction of nonstationary pharmacokinetics and drug interaction magnitude. Drug Metab. Dispos. 2005; 33: 845–852
   PubMed Web of Science ®Google Scholar
• Venkatakrishnan K., Obach R. S. Drug-drug interactions via mechanism-based cytochrome P450 inactivation: points to consider for risk assessment from in vitro data and clinical pharmacologic evaluation. Curr. Drug Metab. 2007; 8: 449–462
   PubMed Web of Science ®Google Scholar
• von Weymarn L. B., Zhang Q. Y., Ding X., Hollenberg P. F. Effects of 8-methoxypsoralen on cytochrome P450 2A13. Carcinogenesis 2005; 26: 621–629
   PubMed Web of Science ®Google Scholar
• von Weymarn L. B., Chun J. A., Hollenberg P. F. Effects of benzyl and phenethyl isothiocyanate on P450s 2A6 and 2A13: potential for chemoprevention in smokers. Carcinogenesis 2006; 27: 782–790
   PubMed Web of Science ®Google Scholar
• Voorman R. L., Maio S. M., Payne N. A., Zhao Z., Koeplinger K. A., Wang X. Microsomal metabolism of delavirdine: evidence for mechanism-based inactivation of human cytochrome P450 3A. J. Pharmacol. Exp. Ther. 1998; 287: 381–388
   PubMed Web of Science ®Google Scholar
• Walsky RL, Obach RS. Validated assays for human cytochrome P450 activities. Drug Metab. Dispos. 2004; 32: 647–660
   PubMed Web of Science ®Google Scholar
• Wang Y. H., Jones D. R., Hall S. D. Prediction of cytochrome P450 3A inhibition by verapamil enantiomers and their metabolites. Drug Metab. Dispos. 2004; 32: 259–266
   PubMed Web of Science ®Google Scholar
• Wang Y. H., Jones D. R., Hall S. D. Differential mechanism-based inhibition of CYP3A4 and CYP3A5 by verapamil. Drug Metab. Dispos. 2005; 33: 664–671
   PubMed Web of Science ®Google Scholar
• Weber W. W., Hein D. W. Clinical pharmacokinetics of isoniazid. Clin. Pharmacokinet. 1979; 4: 401–422
   PubMed Web of Science ®Google Scholar
• Wen X., Wang J. S., Neuvonen P. J., Backman J. T. Isoniazid is a mechanism-based inhibitor of cytochrome P450 1A2, 2A6, 2C19 and 3A4 isoforms in human liver microsomes. Eur. J. Clin. Pharmacol. 2002; 57: 799–804
   PubMed Web of Science ®Google Scholar
• Wenzel S. E., Kamada A. K. Zileuton: the first 5-lipoxygenase inhibitor for the treatment of asthma. Ann. Pharmacother. 1996; 30: 858–864
   PubMed Web of Science ®Google Scholar
• Whittington H. G., Grey L. Possible interaction between disulfiram and isoniazid. Am. J. Psych. 1969; 125: 1725–1729
   PubMed Web of Science ®Google Scholar
• Williams J. A., Hyland R., Jones B. C., Smith D. A., Hurst S., Goosen T. C., Peterkin V., Koup J. R., Ball S. E. Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios. Drug Metab. Dispos. 2004; 32: 1201–1208
   PubMed Web of Science ®Google Scholar
• Winkler P., Lindner W., Esterbauer H., Schauenstein E., Schaur R. J., Khoschsorur G. A. Detection of 4-hydroxynonenal as a product of lipid peroxidation in native Ehrlich ascites tumor cells. Biochim. Biophys. Acta 1984; 796: 232–237
   PubMed Web of Science ®Google Scholar
• Winkler P., Schaur R. J., Schauenstein E. Selective promotion of ferrous ion-dependent lipid peroxidation in Ehrlich ascites tumor cells by histidine as compared with other amino acids. Biochim. Biophys. Acta 1984; 796: 226–231
   PubMed Web of Science ®Google Scholar
• Wiseman L. R., Markham A. Irinotecan. A review of its pharmacological properties and clinical efficacy in the management of advanced colorectal cancer. Drugs 1996; 52: 606–623
   PubMed Web of Science ®Google Scholar
• Wright J. M., Stokes E. F., Sweeney V. P. Isoniazid-induced carbamazepine toxicity and vice versa: a double drug interaction. N. Engl. J. Med. 1982; 307: 1325–1327
   PubMed Web of Science ®Google Scholar
• Yang J., Jamei M., Yeo K. R., Tucker G. T., Rostami-Hodjegan A. Kinetic values for mechanism-based enzyme inhibition: assessing the bias introduced by the conventional experimental protocol. Eur. J. Pharm. Sci. 2005; 26: 334–340
   PubMed Web of Science ®Google Scholar
• Yang J., Jamei M., Yeo K. R., Tucker G. T., Rostami-Hodjegan A. Theoretical assessment of a new experimental protocol for determining kinetic values describing mechanism (time)-based enzyme inhibition. Eur. J. Pharm. Sci. 2007; 31: 232–241
   PubMed Web of Science ®Google Scholar
• Yao K., Falick A. M., Patel N., Correia M. A. Cumene hydroperoxide-mediated inactivation of cytochrome P450 2B1. Identification of an active site heme-modified peptide. J. Biol. Chem. 1993; 268: 59–65
   PubMed Web of Science ®Google Scholar
• Zhao X. J., Jones D. R., Wang Y. H., Grimm S. W., Hall S. D. Reversible and irreversible inhibition of CYP3A enzymes by tamoxifen and metabolites. Xenobiotica 2002; 32: 863–878
   PubMed Web of Science ®Google Scholar
• Zhao P., Kunze K. L., Lee C.A. Evaluation of time-dependent inactivation of CYP3A in cryopreserved human hepatocytes. Drug Metab. Dispos. 2005; 33: 853–861
   PubMed Web of Science ®Google Scholar
• Zhou S., Koh H. L., Gao Y., Gong Z. Y., Lee E. J. Herbal bioactivation: the good, the bad and the ugly. Life Sci. 2004; 74: 935–968
   PubMed Web of Science ®Google Scholar
• Zhou S., Chan E., Lim L. Y., Boelsterli U. A., Li S. C., Wang J., Zhang Q., Huang M., Xu A. Therapeutic drugs that behave as mechanism-based inhibitors of cytochrome P450 3A4. Curr. Drug Metab. 2004; 5: 415–442
   PubMed Web of Science ®Google Scholar
• Zhou S., Yung Chan S., Cher Goh B., Chan E., Duan W., Huang M., McLeod H. L. Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs. Clin. Pharmacokinet. 2005; 44: 279–304
   PubMed Web of Science ®Google Scholar
• Zdravkovic M., Olsen A. K., Christiansen T., Schulz R., Taub M. E., Thomsen M. S., Rasmussen M. H., Ilondo M. M. A clinical study investigating the pharmacokinetic interaction between NN703 (tabimorelin), a potential inhibitor of CYP3A4 activity, and midazolam, a CYP3A4 substrate. Eur. J. Clin. Pharmacol. 2003; 58: 683–688
   PubMed Web of Science ®Google Scholar